FOLH1 and prostate cancer: Given the significantly higher specificity of the 68Ga-labeled ligand targeting the prostate-specific membrane antigen (68Ga-PSMA-11) compared to 11C- or 18F-Choline within the prostate and the superior anatomical allocation of MRI over computer tomography CT (Gunzinger et al., 2014), 68Ga-PSMA-11 PET/MRI is a promising new modality for staging high-risk prostate cancer (PCa) with the potential to improve multiparametric MRI (mpMRI) (Eiber et al., 2015; Thalgott et al., 2018).